Status and Quality of Guidelines for Therapeutic Drug Monitoring Based on AGREE II Instrument

• Published in: Clinical pharmacokinetics Vol. 62; no. 9; pp. 1201 - 1217
• Main Authors: Yi, Zhan-Miao, Li, Xinya, Wang, Zhitong, Qin, Jiguang, Jiang, Dan, Tian, Panhui, Yang, Ping, Zhao, Rongsheng
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2023; Springer Nature B.V
• Subjects: Clinical medicine; Drug dosages; Evidence-based medicine; Internal Medicine; International organizations; Medical research; Medicine; Medicine & Public Health; Methods; Patients; Pharmacology/Toxicology; Pharmacotherapy; Systematic Review; Therapeutic drug monitoring; United Kingdom > UK; United States > US; China
• ISSN: 0312-5963; 1179-1926
• DOI: 10.1007/s40262-023-01283-x

Background With the progress of therapeutic drug monitoring (TDM) technology and the development of evidence-based medicine, many guidelines were developed and implemented in recent decades. Objective The aim was to evaluate the current status of TDM guidelines and provide suggestions for their development and updates based on Appraisal of Guidelines for Research and Evaluation (AGREE) II. Methods The TDM guidelines were systematically searched for among databases including PubMed, Embase, China National Knowledge Infrastructure, Wanfang Data, and the Chinese biomedical literature service system and the official websites of TDM-related associations. The search period was from inception to 6 April 2023. Four researchers independently screened the literature and extracted data. Any disagreement was discussed and reconciled by another researcher. The quality of guidelines was assessed using the AGREE II instrument. Results A total of 92 guidelines were included, including 57 technical guidelines, three management guidelines, and 32 comprehensive guidelines. The number of TDM guidelines has gradually increased since 1979. The United States published the most guidelines (20 guidelines), followed by China (15 guidelines) and the United Kingdom (ten guidelines), and 23 guidelines were developed by international organizations. Most guidelines are aimed at adult patients only, while 28 guidelines include special populations. With respect to formulation methods, there are 23 evidence-based guidelines. As for quality evaluation results based on AGREE II, comprehensive guidelines scored higher (58.16%) than technical guidelines (51.36%) and administrative guidelines (50.00%). Conclusion The number of TDM guidelines, especially technical and comprehensive ones, has significantly increased in recent years. Most guidelines are confronted with the problems of unclear methodology and low quality of evidence according to AGREE II. More evidence-based research on TDM and high-quality guideline development is recommended to promote individualized therapy.